| Common Variable Immunodeficiency
HyQvia vs Octagam 5%
Side-by-side clinical, coverage, and cost comparison for common variable immunodeficiency.Deep comparison between: Hyqvia vs Octagam Immune Globulin (Human) with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOctagam Immune Globulin (Human) has a higher rate of injection site reactions vs Hyqvia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Octagam Immune Globulin (Human) but not Hyqvia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyqvia
Octagam Immune Globulin (Human)
At A Glance
SC injection
Every 3-4 weeks
Immune globulin (IgG replacement)
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 600 mg/kg SC every 3 to 4 weeks after initial ramp-up from 1-week to full dose; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose at each infusion site.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Same dose and frequency as prior IGIV treatment SC, typical dosing interval 4 weeks; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose; ramp-up recommended based on tolerability.
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-600 mg/kg IV every 3-4 weeks; adjust dose over time to achieve desired trough levels and clinical response.
Measles Exposure 400 mg/kg IV as soon as possible and within 6 days of exposure; increase to at least 530 mg/kg every 3-4 weeks if patient is at risk of future measles exposure.
Contraindications
- History of anaphylactic or severe systemic reactions to IgG administration
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Known systemic hypersensitivity to hyaluronidase including rHuPH20
- Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)
- Acute severe hypersensitivity reaction to human immunoglobulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity
- Acute hypersensitivity reaction to corn (product contains maltose derived from corn)
Adverse Reactions
Most common (>5%) Local infusion site reactions (discomfort/pain, erythema, swelling/edema, pruritus), headache, fatigue, nausea, pyrexia, vomiting
Postmarketing Hypersensitivity, influenza-like illness, infusion site leaking, anaphylactic reaction, tremor, tachycardia, hypotension, infusion related reaction, dyspnea, paresthesia oral, dermatitis allergic, injection site rash, alanine aminotransferase increased
Most common (>=5%) headache, nausea
Serious anaphylactic reactions, thromboembolic events, aseptic meningitis, hemolytic anemia
Postmarketing leukopenia, hemolytic anemia, anaphylactic shock, angioedema, cerebrovascular accident, myocardial infarction, pulmonary embolism, renal failure acute, transfusion-related acute lung injury
Pharmacology
Immune globulin (IgG) replacement product in which the Immune Globulin Infusion (Human), 10% supplies broad-spectrum opsonizing and neutralizing IgG antibodies against bacterial and viral agents, while rHuPH20 transiently depolymerizes subcutaneous hyaluronan to increase tissue permeability, facilitating dispersion and absorption of the full IgG dose administered subcutaneously.
Intravenous immunoglobulin G preparation that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacteria and their toxins; restores abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyqvia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Octagam Immune Globulin (Human)
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (7/12) · Qty limit (0/12)
UnitedHealthcare
Hyqvia
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Octagam Immune Globulin (Human)
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Hyqvia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Octagam Immune Globulin (Human)
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Octagam Immune Globulin (Human).
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyqviaView full Hyqvia profile
Octagam Immune Globulin (Human)View full Octagam Immune Globulin (Human) profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.